$MCLE
Medicale Corp.

2024 Q1 Form 10-Q Financial Statement

#000168316824001005 Filed on February 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.60K $19.31K $14.23K
YoY Change 73.2% 121.7% -0.84%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.60K $19.31K $14.23K
YoY Change 73.2% 121.7% -0.84%
Operating Profit -$10.60K -$19.31K
YoY Change 73.39% 121.56%
Interest Expense -$960.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $961.00
YoY Change
Pretax Income -$11.56K -$19.31K -$14.23K
YoY Change 89.11% 121.56% -0.84%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.56K -$19.31K -$14.23K
YoY Change 89.11% 133.77% -0.84%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 5.920M shares 5.920M shares
Diluted Shares Outstanding 5.920M shares 5.920M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $160.00 $160.00 $160.00
YoY Change 0.0% 0.0%
Cash & Equivalents $159.00 $159.00 $159.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $159.00 $159.00 $159.00
YoY Change 0.0% 0.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $159.00 $159.00 $159.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $159.00 $159.00 $159.00
YoY Change 0.0% 0.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $960.00 $0.00 $8.400K
YoY Change -84.31% -77.3%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.96K $12.00K $40.88K
YoY Change -28.45% 0.0% -25.37%
LONG-TERM LIABILITIES
Long-Term Debt $58.79K $48.19K $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $58.79K $48.19K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $12.96K $12.00K $40.88K
Total Long-Term Liabilities $58.79K $48.19K $0.00
Total Liabilities $71.75K $60.19K $40.88K
YoY Change 295.97% 401.55% -25.36%
SHAREHOLDERS EQUITY
Retained Earnings -$148.5K -$136.9K -$117.6K
YoY Change 56.54% 54.29% 46.14%
Common Stock $592.00 $592.00 $592.00
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$71.59K -$60.03K -$40.72K
YoY Change
Total Liabilities & Shareholders Equity $159.00 $159.00 $159.00
YoY Change 0.0% 0.0%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$11.56K -$19.31K -$14.23K
YoY Change 89.11% 133.77% -0.84%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$10.60K -$48.19K -$12.24K
YoY Change 816.26% 244.79%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.60K $48.19K 12.24K
YoY Change 789.37% 244.79%
NET CHANGE
Cash From Operating Activities -10.60K -$48.19K -12.24K
Cash From Investing Activities 0.000 $0.00 0.000
Cash From Financing Activities 10.60K $48.19K 12.24K
Net Change In Cash 0.000 $0.00 0.000
YoY Change -100.0% -100.0%
FREE CASH FLOW
Cash From Operating Activities -$10.60K -$48.19K -$12.24K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001827855
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity File Number
EntityFileNumber
333-250025
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
Medicale Corp.
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1556944
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
9314 Forest Hill Blvd. #929
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Wellington
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33411
CY2023Q4 dei City Area Code
CityAreaCode
407
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
245-7339
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q4 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5920000 shares
CY2023Q4 us-gaap Cash
Cash
159 usd
CY2023Q3 us-gaap Cash
Cash
159 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
159 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
159 usd
CY2023Q4 us-gaap Assets
Assets
159 usd
CY2023Q3 us-gaap Assets
Assets
159 usd
CY2023Q4 MCLE Related Party Advances
RelatedPartyAdvances
0 usd
CY2023Q3 MCLE Related Party Advances
RelatedPartyAdvances
20480 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
0 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8399 usd
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
12000 usd
CY2023Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
12000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
40879 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
48186 usd
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
48186 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 usd
CY2023Q4 us-gaap Liabilities
Liabilities
60186 usd
CY2023Q3 us-gaap Liabilities
Liabilities
40879 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
592 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
592 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
76320 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
76320 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136939 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117632 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-60027 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-40720 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19307 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8714 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-19307 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-8714 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19307 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8714 usd
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-19307 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-8714 usd
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 usd
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
455 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-19307 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-8259 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.00
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.00
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.00
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-54774 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
51192 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-8259 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11841 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-40720 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-19307 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-60027 usd
CY2023Q4 MCLE Income Loss From Continuing Operations1
IncomeLossFromContinuingOperations1
-19307 usd
CY2022Q4 MCLE Income Loss From Continuing Operations1
IncomeLossFromContinuingOperations1
-8714 usd
CY2023Q4 MCLE Income Loss From Discontinued Operations Net Of Tax1
IncomeLossFromDiscontinuedOperationsNetOfTax1
0 usd
CY2022Q4 MCLE Income Loss From Discontinued Operations Net Of Tax1
IncomeLossFromDiscontinuedOperationsNetOfTax1
455 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-8399 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3000 usd
CY2023Q4 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-20480 usd
CY2022Q4 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
5418 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48186 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
159 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
48186 usd
CY2022Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48186 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
159 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159 usd
CY2023Q4 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q4 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q4 MCLE Debt Forgiveness By Related Party
DebtForgivenessByRelatedParty
0 usd
CY2022Q4 MCLE Debt Forgiveness By Related Party
DebtForgivenessByRelatedParty
51192 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136939 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117632 usd
CY2023Q4 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_842_eus-gaap--UseOfEstimates_zZQy6EcP6WN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q4 us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<p id="xdx_841_eus-gaap--RevenueRecognitionMultipleElementArrangements_zrJ2Hb8eqcdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All revenue generated by the Company was done so by operations that have been discontinued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023Q4 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zRcJQNaeZSbk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial Statement Reclassification</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities
DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities
12000 usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities
DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities
12000 usd
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
12000 usd
CY2023Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
12000 usd
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
0 usd
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
455 usd
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
0 usd
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
0 usd
CY2023Q4 us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
-0 usd
CY2022Q4 us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
-0 usd
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 usd
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
455 usd
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.00
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
7200 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 usd
CY2022 MCLE Debt Forgiveness By Related Party
DebtForgivenessByRelatedParty
51192 usd

Files In Submission

Name View Source Status
0001683168-24-001005-index-headers.html Edgar Link pending
0001683168-24-001005-index.html Edgar Link pending
0001683168-24-001005.txt Edgar Link pending
0001683168-24-001005-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mcle-20231231.xsd Edgar Link pending
medicale_ex3100.htm Edgar Link pending
medicale_ex3200.htm Edgar Link pending
medicale_i10q-123123.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mcle-20231231_cal.xml Edgar Link unprocessable
mcle-20231231_def.xml Edgar Link unprocessable
mcle-20231231_lab.xml Edgar Link unprocessable
mcle-20231231_pre.xml Edgar Link unprocessable
medicale_i10q-123123_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable